Merck announces FDA approved KEYTRUDA.
Merck announced that the FDA has approved KEYTRUDA, Merck's anti-PD-1 therapy, for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection based on results from the EORTC1325/KEYNOTE-054 trial. This pivotal Phase 3 trial, which was conducted in collaboration with the European Organisation for Research and Treatment of Cancer, or EORTC, demonstrated that KEYTRUDA significantly prolonged recurrence-free survival, or RFS, reducing the risk of disease recurrence or death by 43% compared to placebo in patients with resected, high-risk stage III melanoma. KEYTRUDA is the first anti-PD-1 therapy studied in the adjuvant setting across patients with stage IIIA, IIIB and IIIC melanoma.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 19, 2019|
|Previous Article:||Etsy error causes withdrawals from some sellers' accounts, TechCrunch reports.|
|Next Article:||Pfizer, Eli Lilly tanezumab Phase 3 study meets primary endpoint.|